We introduce the CS-100* developed after more than 30 years of R & D, and extensive market studies with the innovations focused on the clinical benefit it offers to the population, and also the operational and business benefit it brings to the medical profession.
  • The CS-100 is patented and its proprietary diagnostic software is copyrighted
  • Has U.S.FDA 510(k) clearance reissued in 2004 for non-invasive cardiac testing
  • Has U.S.FDA 510(k) clearance reissued in 2004 for non-invasive cardiac testing
  • The manufacture is in compliance with the standard ISO 9001 and EN ISO 13485 and ISO 9000.
Maximizing the clinician’s time and helping to increase practice revenues. The American Heart Association has set a goal for America — to improve the cardiovascular health of all Americans and to reduce deaths from cardiovascular diseases and stroke by 20 percent by 2020.

Possibles uses

Our commitment to improving the science of early diagnosis of Heart Diseases, has led us to develop the CardioScan-100 (CS-100), a fast, reliable, non invasive cardiac diagnostic test that will be the preferred choice of heart screening in a variety of care settings, maximizing the clinician’s time and helping to increase practice revenues. It can be used at the following:
  • Hospitals and Emergency Facilities
  • Impatient and Outpatient Clinics
  • Physicians Offices
  • Clinical Research Organizations
  • Government Medical Services
  • Insurance Companies
  • Sports Organizations
  • Future application for Ambulances and Airlines use.

The Research

The basic premise underlying the proprietary technology incorporated in the CS-100 is a recognition that time domain myocardial electrical signals can be transformed into frequency domain and then provide a differential analysis.

The human heart is only the size of a fist, but it is the strongest muscle in the body. This remarkable muscle is vulnerable to breakdown and assault from a variety of factors, many of which can be prevented.  CS-100 treats the heart as a mechanical system, and tap applies engineering concepts of system analysis. Our proprietary technology utilizes biocybernetic principles and frequency analysis in a non-invasive medical device that applies new dimensions of mathematical and physical formulae, including Fourier and LaPlace transformations. It transforms the recordings of the conventional 12-lead ECG (recorded in less than 2 minutes) from the time domain to the frequency domain, thus enabling it to read more precise indexes of heart function such as power spectrum, coherence, cross-correlation, amplitude histogram, impulse response, phase shift and transfer function.

Since CardioScan evaluates the function of the myocardium directly, it can detect any early subtle changes in myocardial function or injuries caused by the obstruction of small coronary arteries which cannot be detected by other testing methods. It is a new member to the family of the cardiac diagnostic modalities. The clinical application of this new set of indices through the use of CardioScan-100, especially the impairment of myocardial function due to coronary insufficiency, has been impressively successful and the device has been recognized by a number of world renowned cardiologists to be a medical breakthrough in the field of early and non-invasive detection of heart diseases.